Core Viewpoint - The company announced the cancellation and repurchase of certain unvested restricted stocks due to unmet performance conditions in the first unlock period of the 2023 restricted stock incentive plan [1][10][12]. Summary by Sections 1. Announcement of Stock Repurchase - The company plans to repurchase and cancel a total of 1,818,050 shares of restricted stock that were granted but not unlocked, following the decision made in the board meeting on August 21, 2025 [1][7][10]. 2. Background of the Incentive Plan - The 2023 restricted stock incentive plan was approved through a series of meetings and public disclosures, with the first unlock period set to occur 24 months after the grant date [2][3][4]. 3. Performance Conditions - The performance conditions for unlocking the restricted stocks were based on achieving specific revenue growth rates and return on equity benchmarks, which were not met for the first unlock period [8][10]. 4. Details of the Repurchase - The repurchase will involve 75,000 shares from two individuals who left the company and 1,743,050 shares from the remaining 60 incentive plan participants whose performance did not meet the required targets [6][10][12]. 5. Financial Impact - The repurchase amount is relatively small and is not expected to significantly impact the company's financial status or operational results [12]. 6. Compliance and Approval - The board and supervisory committee have confirmed that the repurchase process complies with relevant laws and regulations, and it requires approval from the shareholders' meeting [12][13].
信隆健康: 关于2023年限制性股票激励计划第一个解除限售期解除限售条件未成就暨回购注销部分限制性股票的公告